Two COVID-19 vaccine products for young children are nearing the final stages of the Emergency Use Authorization (EUA) process. Pfizer-BioNTech is submitting data on a THREE-dose primary series for a vaccine for children ages six months through FOUR years of age (6m–4y). Moderna is submitting data on a TWO-dose primary series for children ages six months through FIVE years of age (6m–5 y). The authorization is a multi-step clinical and regulatory process, and no vaccine can be administered until the final recommendation is issued by the CDC Director, Dr. Walensky. In preparation, this guidance includes details about BOTH products.
top of page
Recent PostsSee All
Looking for an exciting new opportunity? NY State is looking for a Director of the Vaccine Division. Details below. StateJobsNY - State Employees: Review Vacancy
Agenda Kids today are immersed in digital media more than ever – and they start consuming media at much a much younger age. There are risks and benefits that come with media use. The key is to develop
At this year’s conference, FrameWorks’ Dr. Julie Sweetland gave an informative presentation and workshop on how to address COVID-19 vaccine misinformation with families. For those interested in how to
bottom of page